Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic options for LUSC remain limited, primarily due to the absence of well-defined, ...
Camrelizumab plus chemotherapy doubled the five-year survival rate in advanced squamous lung cancer to 27.8%, reducing mortality risk by 43%. The CameL-sq trial demonstrated camrelizumab's efficacy as ...
Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...
or on the link below. Squamous cell carcinoma of the lung (LUSC) stands as the second most prevalent form of non–small cell lung cancer (NSCLC), constituting 20%-30% of patients with NSCLC diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results